SAB BiotherapeuticsvsUnitedHealth

SABS and UNH stock compared: price, dividend, valuation and results, from SEC filings.

SABS

SAB Biotherapeutics, Inc.

$2.81

Value $253M

-3.44%
SABS's page

UNH

UnitedHealth Group Incorporated

$339.85

Value $308B

+2.84%
UNH's page

SAB Biotherapeutics (SABS) has a market value of $253M and UnitedHealth (UNH) $308B. Over the last year, with dividends, SABS moved -26.6% and UNH +12.9%. Dividend yield: SABS none, UNH 2.67%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    SABS$253M

    UNH$308B

    UNH is 1,219 times SABS

  • Revenue, 12 months

    SABS$0

    UNH$450B

  • Net income, 12 months

    SABS-$81M

    UNH$15.9B

  • Operating margin

    SABS–

    UNH5.3%

  • ROIC

    SABS-25.5%

    UNH11.3%

    36.8 points apart

  • P/E

    SABS–

    UNH19.4

  • Dividend yield

    SABS0.0%

    UNH2.7%

    2.7 points apart

  • 5-year return

    SABS-97.5%

    UNH-15.4%

    82.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

SABS-97.5%

UNH-15.4%

05010015020222023202420252026
Returns by period
PeriodSABSWith dividendsUNHWith dividends
1 year since November 19, 2025-26.6%Price -26.6%+12.9%Price +10.0%
3 years since November 20, 2023-66.3%-30.4% a yearPrice -66.3%-32.4%-12.2% a yearPrice -36.5%
5 years since November 19, 2021-97.5%-52.0% a yearPrice -97.5%-15.4%-3.3% a yearPrice -22.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

SABSSAB BiotherapeuticsUNHUnitedHealth

Valuation

SABSUNH
Valuation
Price$2.81$339.85
Market value$253M$308B
Enterprise value (EV)$152M$354B
P/E–19.4
P/E, 5-year median–25.0
P/B1.23.0
EV/EBIT–14.8
Free cash flow yield–7.4%

Results and growth

SABSUNH
Results and growth
Revenue, 12 months$0$450B
Net income, 12 months-$81M$15.9B
Free cash flow, 12 months-$46M$22.8B
Earnings per share, 12 months-$1.33$17.52
Revenue growth, year on year-100.0%11.8%
Revenue growth a year, past–+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

SABSUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin–5.3%
Net margin–3.5%
ROIC-25.5%11.3%
ROE-41.5%15.5%

Balance sheet

SABSUNH
Balance sheet
Cash$104M$28.5B
Total debt$4.9M$74.3B
Net debt / EBITDA–1.6
Interest cover-211.2×6.2×

Dividends and buybacks

SABSUNH
Dividends and buybacks
Dividend yield–2.7%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: SABS or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, SAB Biotherapeutics or UnitedHealth?

By market value, UnitedHealth ($308B) is about 1,218.5 times SAB Biotherapeutics ($253M), at today's prices.

How did SABS and UNH stock do over the last 5 years?

Since November 19, 2021, SABS's price moved -97.5% and UNH's -22.8%. With dividends: SABS -97.5% (-52.0% a year), UNH -15.4% (-3.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, SABS or UNH?

The dividend yield at today's price is none for SAB Biotherapeutics and 2.67% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which is the better investment, SAB Biotherapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.